{
    "clinical_study": {
        "@rank": "163390", 
        "brief_summary": {
            "textblock": "Patients undergoing immunotherapy for advanced cancer under IRB-approved protocols, who are\n      to receive immune cells in adoptive transfer, will have less than or equal to 50% of those\n      cells labeled with In-111-oxine and administered along with the remainder of their unlabeled\n      cells.  They will then undergo gamma-camera imaging over the next 0-7 days and blood samples\n      and tumor sites which are accessible with minimal surgery (low-risk biopsy) may be sampled\n      in some patients for enumeration of radiolabeled cells.  End-points will be tumor and normal\n      organ imaging and the amount of In-111 per gram of tissue in biopsies or per ml. of blood."
        }, 
        "brief_title": "Trafficking of Indium-III-Labeled Cultured Immune Cells in Patients Undergoing Immunotherapy for Advanced Cancer", 
        "completion_date": "December 2002", 
        "condition": "Neoplasm", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Patients undergoing immunotherapy for advanced cancer under IRB-approved protocols, who are\n      to receive immune cells in adoptive transfer, will have less than or equal to 50% of those\n      cells labeled with In-111-oxine and administered along with the remainder of their unlabeled\n      cells.  They will then undergo gamma-camera imaging over the next 0-7 days and blood samples\n      and tumor sites which are accessible with minimal surgery (low-risk biopsy) may be sampled\n      in some patients for enumeration of radiolabeled cells.  End-points will be tumor and normal\n      organ imaging and the amount of In-111 per gram of tissue in biopsies or per ml. of blood."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION CRITERIA\n\n        All patients will be 18 years of age or older.\n\n        All patients will be enrolled in NCI-approved intramural immunotherapy protocol in which\n        immune cells are adoptively administered to treat advanced cancer.\n\n        EXCLUSION CRITERIA\n\n        Patients who are receiving less than 3x10(9) cells in transfer will be excluded.\n\n        Impaired patients who are unable to give valid informed consent will also be excluded.\n\n        Patients who are pregnant will be excluded.\n\n        All other exclusion criteria stated in the parent immunotherapy protocol.\n\n        Patients who are HIV-infected."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "100", 
        "firstreceived_date": "November 14, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00026897", 
            "org_study_id": "980033", 
            "secondary_id": "98-C-0033"
        }, 
        "intervention": [
            {
                "intervention_name": "Gamma-camera imaging", 
                "intervention_type": "Procedure"
            }, 
            {
                "intervention_name": "Low-risk biopsy", 
                "intervention_type": "Procedure"
            }
        ], 
        "keyword": [
            "Adoptive Immunotherapy", 
            "Cellular Therapy", 
            "Lymphocyte Migration", 
            "Tumor Imaging"
        ], 
        "lastchanged_date": "March 3, 2008", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Cancer Institute (NCI)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Trafficking of Indium-111-Labeled Cultured Immune Cells in Patients Undergoing Immunotherapy for Advanced Cancer", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "reference": [
            {
                "PMID": "3486223", 
                "citation": "Shu S, Chou T, Rosenberg SA. In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells. J Immunol. 1986 May 15;136(10):3891-8."
            }, 
            {
                "PMID": "2953816", 
                "citation": "Shu SY, Chou T, Rosenberg SA. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. J Immunol. 1987 Jul 1;139(1):295-304."
            }, 
            {
                "PMID": "3264384", 
                "citation": "Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988 Dec 22;319(25):1676-80."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00026897"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "December 1997", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2002"
    }, 
    "geocoordinates": {
        "National Cancer Institute (NCI)": "38.985 -77.095"
    }
}